Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

nivolumab (OPDIVO ®), for the treatment of patients with resectable hepatic-limited metastatic colorectal cancer (mCRC). Bavarian Nordic's CV301 is designed to create a T-cell response against the tum...

Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) combination is the first and only treatment to show significantly superior overall survival versus current standard of care in intermediate- and poor-risk ad...